@article{cda685c841944ace85f2ba3b334a2ef6,
title = "Blockade of latent inhibition following pharmacological increase or decrease of GABA(A) transmission",
abstract = "The latent inhibition (LI) phenomenon refers to the retardation in learning of an association between a stimulus and a consequence if that stimulus had been previously experienced without consequence. An earlier study demonstrated that the benzodiazepine receptor agonist chlordiazepoxide (CDP), when administered before the phase of preexposure to the to-be-conditioned stimulus, impaired animals' ability to develop LI. The present study was designed to investigate the effect of the anxiogenic drugs pentylenetetrazole (PTZ) and the benzodiazepine partial inverse agonist Ro15-4513 on LI. Both anxiogenics, in contrast to CDP, are known for their GABA inhibitory action. The effects produced by the combined administration of a GABAergic function facilitator and inhibitor (CDP/PTZ and CDP/Ro15-4513) were also investigated. Both anxiogenic drugs led to an attenuation of LI, and, similarly to CDP, this attenuation was exclusively due to their administration prior to the preexposure stage of the experiment. However, this effect was abolished when anxiolytic and anxiogenic drugs were administered together, suggesting a pharmacological rather than behavioral summation of effects. These data also demonstrate the bidirectional GABAergic modulation of the LI phenomenon: both increased and decreased GABA(A) receptor activation led to reduced LI, thereby suggesting that an optimal receptor activation level is necessary for the normal establishment of LI. Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Attention, Chlordiazepoxide, GABA(A) receptors, Latent inhibition, Pentylenetetrazole, Rat, Ro15-4513",
author = "Laurent Lacroix and Simona Spinelli and Broersen, {Laus M.} and Joram Feldon",
note = "Funding Information: This work was supported by grants from the Swiss Federal Institute of Technology and the Swiss National Science Foundation (Grant No. 31-42009.94). The authors gratefully acknowledge the insightful comments and criticism of Dr. J. Lehmann and Dr. I. Weiner (Department of Psychology, Tel-Aviv University, Tel-Aviv, 69978 Israel) for her helpful discussions on part of the results. Special thanks are due to Prof. H. M{\"o}hler (Institute of Pharmacology, Swiss Federal Institute of Technology, ETH Zurich, Switzerland), for his expert advice on the pharmacology of GABA-BZD ligands, Dr. W. White for his invaluable help, P. Schmid for expert technical support, the animal care team for their assistance, and B. Strehler for her help with the preparation of the manuscript.",
year = "2000",
month = aug,
doi = "10.1016/S0091-3057(00)00269-0",
language = "אנגלית",
volume = "66",
pages = "893--901",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "4",
}